164 related articles for article (PubMed ID: 33128734)
1. Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
Sendi P
Pharmacoeconomics; 2021 Feb; 39(2):161-169. PubMed ID: 33128734
[TBL] [Abstract][Full Text] [Related]
2. Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Sendi P; Matter-Walstra K; Schwenkglenks M
Healthcare (Basel); 2021 Oct; 9(11):. PubMed ID: 34828466
[TBL] [Abstract][Full Text] [Related]
3. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
Elbasha EH
Pharmacoeconomics; 2022 May; 40(5):497-507. PubMed ID: 35137340
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
Sendi P; Gafni A; Birch S; Walter SD
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33799361
[TBL] [Abstract][Full Text] [Related]
5. A risk-adjusted approach to comparing the return on investment in health care programs.
Sendi P; Al MJ; Zimmermann H
Int J Health Care Finance Econ; 2004 Sep; 4(3):199-210. PubMed ID: 15277778
[TBL] [Abstract][Full Text] [Related]
6. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
7. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
8. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
Sendi P; Al MJ; Gafni A; Birch S
Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
[TBL] [Abstract][Full Text] [Related]
9. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
10. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
11. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
12. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
Sendi PP; Briggs AH
Health Econ; 2001 Oct; 10(7):675-80. PubMed ID: 11747050
[TBL] [Abstract][Full Text] [Related]
13. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.
Sendi P; Al MJ
Soc Sci Med; 2003 Sep; 57(6):969-74. PubMed ID: 12878098
[TBL] [Abstract][Full Text] [Related]
15. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis.
Alfirevic Z; Keeney E; Dowswell T; Welton NJ; Medley N; Dias S; Jones LV; Gyte G; Caldwell DM
Health Technol Assess; 2016 Aug; 20(65):1-584. PubMed ID: 27587290
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness league tables: valuable guidance for decision makers?
Mauskopf J; Rutten F; Schonfeld W
Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
[TBL] [Abstract][Full Text] [Related]
17. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada.
Isaranuwatchai W; Alam F; Hoch J; Boet S
J Educ Eval Health Prof; 2017; 13():44. PubMed ID: 28028288
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ovarian stimulation agents for IUI in couples with unexplained subfertility.
van Eekelen R; Wang R; Danhof NA; Mol F; Mochtar M; Mol BW; van Wely M
Hum Reprod; 2021 Apr; 36(5):1288-1295. PubMed ID: 33615360
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
